Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 Combined With Nivolumab in Metastatic Gastric Cancer
NCT06008925Phase 2Recruiting
- Sponsor
- Virogin Biotech
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Virogin Biotech. Started Nov 2022; status: recruiting.
02
Drugs
VG161
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06008925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008925.